Skip to Main Content

Paper Details

Neoadjuvant eribulin in HER2-negative early-stage breast cancer (SOLTI-1007-NeoEribulin): a multicenter, two-cohort, non-randomized phase II trial.
NPJ Breast Cancer
9
2021
Basal, Basal-, Basal-like, Eribulin, HER2, HER2-negative disease, HER2-negative early-stage breast cancer, HR, Luminal A, Luminal B, Normal, Normal-like, Patients, SOLTI-1007, TILs, TNBC, advanced breast cancer, eribulin, patients, triple-negative breast cancer, tumor, tumor gene, tumor-infiltrating lymphocytes
Author NameAffiliation
Tomás Pascual
Isabel T RubioVall d'Hebron Institute of Oncology (VHIO), Hospital Universitari Vall d'Hebron, Vall d'Hebron Barcelona Hospital Campus
José BaselgaMemorial Sloan Kettering Cancer Center
  • 1 - 3

Datasets

Release 1.2